Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6147414rdf:typepubmed:Citationlld:pubmed
pubmed-article:6147414lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:6147414lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:6147414lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:6147414lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:6147414lifeskim:mentionsumls-concept:C1611588lld:lifeskim
pubmed-article:6147414pubmed:issue9lld:pubmed
pubmed-article:6147414pubmed:dateCreated1984-10-3lld:pubmed
pubmed-article:6147414pubmed:abstractTextA series of some novel N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamides involving replacement of the sulfamoyl group in sulpiride with a sulfonamido group was synthesized and tested for dopamine receptor blockade. In comparison with sulpiride, several compounds were considerably more potent than sulpiride as dopamine receptor blockers. The structure-activity relationships are discussed.lld:pubmed
pubmed-article:6147414pubmed:languageenglld:pubmed
pubmed-article:6147414pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147414pubmed:citationSubsetIMlld:pubmed
pubmed-article:6147414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147414pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6147414pubmed:statusMEDLINElld:pubmed
pubmed-article:6147414pubmed:monthSeplld:pubmed
pubmed-article:6147414pubmed:issn0022-2623lld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:OgataMMlld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:MatsumotoHHlld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:HiroseKKlld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:ShiomiTTlld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:EigyoMMlld:pubmed
pubmed-article:6147414pubmed:authorpubmed-author:KidaSSlld:pubmed
pubmed-article:6147414pubmed:issnTypePrintlld:pubmed
pubmed-article:6147414pubmed:volume27lld:pubmed
pubmed-article:6147414pubmed:ownerNLMlld:pubmed
pubmed-article:6147414pubmed:authorsCompleteYlld:pubmed
pubmed-article:6147414pubmed:pagination1137-41lld:pubmed
pubmed-article:6147414pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:meshHeadingpubmed-meshheading:6147414-...lld:pubmed
pubmed-article:6147414pubmed:year1984lld:pubmed
pubmed-article:6147414pubmed:articleTitleSynthesis and neuroleptic activity of N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-5-sulfonamidobenzamide s.lld:pubmed
pubmed-article:6147414pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:6147414lld:chembl